Rua Bioscience delivered a sharp rise in customer revenue and secured a UK agreement expected to generate NZ$10 million over two years. But PwC disclaimed an audit opinion, warning the company may not have enough cash without another capital raise.
- Customer revenue up 71% to NZ$2.58 million
- PwC disclaims opinion over going-concern uncertainty
- NZ$2.83 million one-for-three rights offer launched
- UK agreement expected to generate NZ$10 million over two years
- Cash operating outflows reached NZ$2.96 million
Revenue growth collides with a funding shortfall
Rua Bioscience Limited (NZX:RUA) has produced its strongest revenue growth to date, but the medicinal cannabis company’s annual report carries a more sobering message: its next stage of expansion depends on raising more money. Customer revenue rose 71% to NZ$2.58 million in FY26, while total revenue and other income climbed 53% to NZ$2.90 million. Yet PwC disclaimed an audit opinion after concluding it could not obtain enough evidence to resolve material uncertainty over Rua’s ability to continue as a going concern.
The auditor pointed to a NZ$3.36 million loss before tax, net operating cash outflows of NZ$2.96 million and forecasts showing that Rua would not have enough cash to meet minimum commitments and maintain its current level of activity without additional capital. The company held NZ$533,698 in cash at 30 June, against total borrowings of NZ$1.72 million and current liabilities of NZ$2.89 million.
Rights offer targets working capital
Rua has responded with a one-for-three renounceable rights offer priced at NZ$0.025 a share, seeking up to NZ$2.83 million through the issue of about 113.15 million new shares. The offer is not underwritten. Existing shareholders who take up their entitlements in full can apply for additional shares, while any shortfall may be placed with new investors at the same price.
The proposed funding is intended primarily for inventory, working capital, marketing and operating expenses. Rua says the money is needed to fulfil demand in the United Kingdom, Australia and Aotearoa New Zealand, while supporting its emerging positions in Germany, Czechia and Canada. The issue price represents a 32% discount to the 20-day volume-weighted average price cited in the offer materials, and shareholders who do not participate face dilution.
UK agreement offers commercial upside
The capital call is being made against a materially more promising commercial backdrop than Rua’s headline loss might suggest. After year-end, the company signed its largest export agreement with a major UK medicinal cannabis clinic and distribution business, with expected revenue of about NZ$10 million over its initial two-year term. That figure is an expectation rather than guaranteed revenue, and Rua’s own materials say it depends on sufficient funding and the successful execution of the supply arrangement.
FY26 also brought almost doubled Australian sales revenue and margin, higher New Zealand revenue and market share, first revenue in Czechia, and the export of live cannabis clones to Canada. In Germany, Rua said supplier negotiations had reduced delivered costs by close to 50%. These developments give the company several routes to growth, but they do not remove the immediate requirement to finance inventory before sales are collected.
Audit uncertainty extends beyond cash
PwC also withheld assurance on several asset assumptions. Rua carries NZ$2.19 million of goodwill, NZ$1.74 million of property, plant and equipment and NZ$866,765 of assets held for sale. The auditor could not obtain sufficient evidence to support the revenue and margin forecasts underpinning the goodwill valuation, or the fair-value assessment of the Gisborne facility, which has been marketed without a committed buyer.
Rua says its going-concern assessment also relies on a potential facility sale, the renewal or refinancing of existing debt, forecast revenue growth and a successful equity raise. A NZ$300,000 drawdown under a convertible note facility had improved liquidity after year-end, while NZ$592,000 of existing debt had been rolled over and NZ$48,000 repaid. The company nevertheless acknowledged uncertainty around the amount and timing of future funding, the facility sale and debt renewals.
The next test is conversion, not ambition
Rua’s capital-light model avoids owning large-scale cultivation and manufacturing infrastructure, but it still requires cash to buy or secure product ahead of international sales. The rights offer therefore represents a test of whether shareholders will fund the gap between commercial opportunity and operating self-sufficiency.
The decisive evidence will come from cash rather than presentation milestones: how much the offer raises, whether the UK agreement converts into recurring deliveries and revenue, and whether Rua can narrow its operating deficit before its funding runway again becomes the central story.
Bottom Line?
Rua has more commercial traction, but the rights offer and the UK contract must now translate into cash quickly enough to address the going-concern warning.
Questions in the middle?
- How much of the NZ$2.83 million rights offer will be subscribed, given that it is not underwritten?
- When will the UK agreement begin contributing meaningful recognised revenue and cash receipts?
- Can Rua complete the Gisborne facility sale or refinance maturing debt before further capital is required?